格隆汇7月21日丨健世科技-B(09877.HK)发布公告，公司核心产品之一经导管主动脉瓣置换("TAVR")产 品Ken-Valve已于全国重点省市地区的一系列医院成功完成首批商业化植入，最大使用瓣膜型号为 33mm，最短器械操作时间约5分钟。在刚刚结束的2025华西微创心血管大会暨第八届西部瓣膜论坛 中，Ken-Valve顺利完成多例手术直播，成功为多位解剖结构复杂，其中包括超大瓣环、大横位心的患 者，完成主动脉瓣介入置换术。Ken-Valve设计特点、操作优势、适用范围获得与会专家的热烈讨论和 关注。 Ken-Valve是公司自主开发的第一代经导管主动脉瓣置换系统，为治疗重度主动脉瓣反流或合并主动脉 瓣狭窄的患者而设计。Ken-Valve是市场上较为稀缺的治疗主动脉瓣反流(或合并狭窄)的TAVR产品。 Ken-Valve采用一体式夹持定位键设计，提高瓣膜固定稳定性；输送系统具备主动调弯设计，有效提升 瓣膜植入同轴性；拥有最大可达33mm的多个瓣膜规格型号，能够满足广泛未被满足的超大瓣环主动脉 瓣反流或合并狭窄患者的迫切临床需求。 首批商业化植入的成功开展标志着Ken-Valve在中国的商业化应用成功启动 ...

Group 1 - The third China International Supply Chain Promotion Expo showcased innovative health testing products, including gene testing for alcohol sensitivity and real-time ultrasound checks [1][2] - BGI Group introduced a proprietary "micro-sequencing" technology aimed at making gene testing as accessible as blood glucose and blood pressure monitoring, allowing for quick alcohol metabolism capability assessments [1][3] - The mini-sequencer and portable ultrasound device are designed to make advanced medical technology more accessible, with applications in public health and personalized healthcare solutions [2][3] Group 2 - BGI Genomics, as a leading company in the gene sequencing equipment sector in China, has over 3,300 users across research and clinical fields, contributing to daily scientific advancements [3] - The company emphasizes the importance of collaboration and resilience in advancing life sciences and health technology applications, aiming to establish industry standards and an open ecosystem [3]

截至2025年7月18日收盘，天益医疗(301097)报收于42.92元，上涨1.11%，换手率6.02%，成交量1.1万 手，成交额4708.81万元。 当日关注点 交易信息汇总 7月18日，天益医疗的资金流向情况如下：主力资金净流入373.63万元；游资资金净流出283.81万元；散 户资金净流出89.82万元。 公司公告汇总 五方监管协议由公司、新加坡子公司、泰国孙公司、中国工商银行（泰国）股份有限公司及保荐机构国 泰海通证券股份有限公司共同签署，旨在规范募集资金管理，保护中小投资者权益。协议规定了专户仅 用于"泰国生产基地建设项目"的存储和使用，明确了各方的权利和义务，包括资金使用的监督、对账单 的出具、资金支取的通知机制等。协议自各方签署之日起生效，至专户资金全部支出完毕并依法销户之 日起失效。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 交易信息汇总: 主力资金净流入373.63万元，而游资和散户资金分别净流出283.81万元和89.82万 元。 公司公告汇总: 天益医疗已完成开设募集资金专项账户并签署了五方监管协议 ...

Core Viewpoint - The company is currently facing potential challenges due to new EU regulations limiting Chinese medical device companies' participation in public tenders valued over 5 million euros, but it has not yet impacted its business in the EU region [3][4]. Group 1: Stock Performance - As of July 18, 2025, the company's stock closed at 35.13 yuan, with an increase of 0.66%, a turnover rate of 0.78%, a trading volume of 73,500 shares, and a transaction value of 257 million yuan [1]. Group 2: Shareholder Information - As of July 10, 2025, the total number of shareholders for the company was over 40,000 [2][5]. Group 3: Business Operations and Market Presence - The company has established diversified sales channels in the European market, focusing on non-public medical channels through retail pharmacies and partnerships with medical device distributors, which constitute a significant portion of its European sales [3][4]. - The company's overseas business primarily targets Southeast Asia, South America, Western Europe, and the Commonwealth of Independent States, covering over 100 countries and regions globally [6]. Group 4: Capital Flow - On July 18, 2025, the capital flow data indicated a net outflow of 8.87 million yuan from institutional investors, while retail investors showed a net inflow of 10.35 million yuan [7][8].

自2024年9月首届活动举办以来，中韩初创企业对接交流会累计邀请54家韩国"专精特新"企业来沈阳推 介，覆盖医疗器械、人工智能、生物医药等六大战略性新兴产业，已有17家企业达成合作意向，8个项 目签署协议，1个项目成功落地，成果丰硕。 中新网沈阳7月20日电 (李晛)由沈阳市贸促会、韩国驻沈阳总领事馆、中韩国际经贸产业园共同主办的 第六次"中韩(沈阳)初创企业对接交流会"近日在沈阳举办。 本次交流会吸引了来自韩国医学及药品研发、医疗器械、制造业、生物科技、半导体、人工智能等领域 的8家优质初创企业，阵容强大、领域多元。交流会通过路演展示、一对一洽谈等形式，助力沈阳本地 企业与韩国初创企业精准对接。活动现场，韩国KG-BIO公司与沈阳安娜科技有限公司成功签署项目合 资合作协议，标志着产业园在推动中韩项目落地方面再结硕果。 沈阳市贸促会、韩国驻沈阳总领事馆、中韩国际经贸产业园始终致力于打造"科技孵化+金融支撑+产业 落地"的全链条服务体系。本次交流会不仅促成了企业间的技术合作，还推动了韩国仁川市政府拟在沈 阳设立商品体验馆的计划，这将是韩国在沈阳的首家城市商品体验馆。 据悉，作为东北亚国际化合作的重要平台，中韩国 ...

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, suggesting that the sector will experience a reversal in 2025 [4]. Core Views - The innovative drug sector continues to be the main investment theme, with a focus on dual/multi-antibody drugs for various cancers and chronic disease drugs that meet unmet clinical needs [2][4]. - The report highlights the strong performance of leading pharmaceutical companies, such as China Biologic Products and Hansoh Pharmaceutical, following the clearance of procurement risks after multiple rounds of generic drug procurement [12]. - The report emphasizes the potential of the rose acne treatment market, with the announcement of CKBA cream's acceptance for clinical trials, indicating a significant opportunity for innovative therapies in this area [38][45]. Summary by Sections Pharmaceutical Sector - The innovative drug market is showing strong upward momentum, with the A-share innovation drug index rising over 6% and the H-share index increasing over 14% [19]. - The report notes that 48 out of 52 listed companies in the A-share innovative drug sector experienced stock price increases, with an average rise of 10.5% [22]. - The report suggests focusing on innovative drug pipelines that address chronic diseases and unmet clinical needs, particularly in the context of potential overperformance in semi-annual reports [2][4]. Biologics - The approval of semaglutide for chronic kidney disease (CKD) indicates a growing interest in GLP-1 class drugs beyond weight management and type 2 diabetes [2]. Medical Devices - Domestic innovative products continue to receive approvals, with leading companies like Xinmai Medical showing promising recovery in performance [3]. Traditional Chinese Medicine - Companies in the traditional Chinese medicine sector are actively seeking new growth points through new drug pipelines, particularly in weight loss and diabetes treatment [3]. Market Potential - The global market for rosacea treatment is projected to grow from approximately $2.12 billion in 2024 to around $4.23 billion by 2034, with a compound annual growth rate of 7.14% [45][47]. - The report highlights the lack of effective treatments for rosacea, indicating a significant unmet need and potential for innovative therapies [48].

在中国心血管精准诊疗领域长期被进口产品垄断的背景下，北芯生命用九年时间完成"破局"，推动我国 冠心病临床精准诊断进入国产创新时代。作为截至目前国内唯一掌握完整的微型MEMS压力传感器模块 设计与封装技术，以及国内唯一掌握60MHz高频微型超声换能器开发与加工制造并产业化生产的企 业，其核心技术均源于自主研发，且具备行业先进性，攻克了多项"卡脖子"的技术壁垒。 其拳头产品IVUS系统以60MHz成像分辨率、高速的回撤速度和断面成像速度、智能化操作三大特性， 在国产市场中占据重要地位。值得关注的是，该系统作为首个获批欧盟MDR的国产自研IVUS系统，已 成功进军国际市场。另一款自主研发的核心产品FFR(血流储备分数)系统，作为国内首个获批的国产金 标准FFR系统，被国家药监局评价为"国际领先、国内首创并填补空白的产品"，进一步体现了北芯生命 在心血管精准介入领域的技术领先。 在创新研发体系建设上，北芯生命构建了微纳器件研发与封装、介入导管研发与工艺、高性能医疗硬件 开发、高性能信号与图像算法及应用软件四大核心技术平台，奠定了其在心血管疾病精准介入医疗器械 领域持续创新发展的重要基础。 2025未来医疗医药100强 ...

国际在线报道（记者 田媛媛）：第三届中国国际供应链促进博览会（以下简称"链博会"）期间，国际在线 记者专访了来自欧莱雅、普华永道、GE医疗等领军企业高管，受访嘉宾一致表示，中国正加速从"世界工 厂"向"全球供应链创新枢纽"跃进。依托全工业门类优势和敏捷且强韧的供应链体系，中国已成为驱动全球 产业变革的核心引擎。 欧莱雅北亚及中国公共事务总裁兰珍珍 欧莱雅：中国供应链的韧性和创造力值得让全世界看到 普华永道中国公共事务主管合伙人周星表示，链博会是为应对全球供应链挑战提供解决方案的关键平台， 助力各国企业在差异对比中取长补短。凭借超大规模市场、顶尖高科技人才和前沿研发实力三大优势，中 国已从"世界工厂"跃升为"全球创新中心"，正成为连接全球供应链的核心枢纽。她称赞链博会平台既促进 中外企业深度交流，更有助于跨国企业协作共赢，使中国成为优化全球产业链的独特桥梁。 普华永道中国公共事务主管合伙人周星 GE医疗中国副总裁、供应链总经理陈和强 GE医疗：中国是全球高端医械智造与绿色创新引擎 GE医疗中国副总裁、供应链总经理陈和强认为，链博会是展现国产供应链创新与韧性的"中国舞台"。他介 绍称，GE医疗联合多家公司发起成立 ...

Group 1 - The core viewpoint of the articles highlights that Nanwei Medical's stock price closed at 77.08 yuan, with a PE ratio of 25.37, marking a new low in 166 days, and a total market capitalization of 14.479 billion yuan [1] - The average PE ratio for the medical device industry is 52.34, with a median of 36.99, placing Nanwei Medical at the 53rd position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Nanwei Medical increased to 13,313, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Nanwei Medical specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, EMR/ESD devices, dilation devices, ERCP devices, EUS/EBUS devices, ablation instruments, disposable biliary imaging systems, disposable bronchoscopes, and related consumables [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 699 million yuan, representing a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year growth of 12.18%, with a gross profit margin of 65.69% [1]